A Pilot Study to Investigate Biomarkers in Anterior Cruciate Ligament (ACL) Patients and Healthy Controls

NCT ID: NCT02300012

Last Updated: 2022-05-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-05

Study Completion Date

2022-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Incident rates of ACL rupture are greatest in 16-39 year olds at almost 1 in 1,000.

Performance Based Investigations (PBIs) can be used to evaluate and select correct approaches to patient treatment, and biochemical, biomechanical and physiological biomarkers in other conditions are sensitive in distinguishing between disease state severities, type of injuries and responsiveness to treatment. Despite the measurement sensitivity of PBIs, these are not widely used possibly owing to their focus postoperatively where benefits are less worthwhile.

This study aims to investigate novel biomarkers as performance based investigations (PBIs) to improve surgical and treatment strategies in anterior cruciate ligament (ACL) patients. The objectives are to identify whether biomarkers, collected before and after operations, can: 1) Assist the surgeon in decision making; 2) Lead to improved prognosis; 3) Be used to predict the outcomes of prognosis, and; 4) Correlate with disease signs/ smoking to help further understand ACL injuries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rupture of Anterior Cruciate Ligament

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Operation - No PBI

Patients requiring operation - baseline PBI data not seen by surgeon

Group Type NO_INTERVENTION

No interventions assigned to this group

Operation - PBI available

Patients requiring operation - baseline PBI data seen by surgeon pre-operatively

Group Type EXPERIMENTAL

Surgeons knowledge of pre-operative PBIs

Intervention Type PROCEDURE

Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice

Non-operation

Patients with ACL rupture not requiring operation

Group Type NO_INTERVENTION

No interventions assigned to this group

Control

Healthy age matched volunteers - No operation

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgeons knowledge of pre-operative PBIs

Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* unilateral ACL rupture
* 18 - 45 years old

Exclusion Criteria

* combined posterior and ACL rupture
* multi-ligament instability including medial or lateral collateral ligament injury
* other lower limb surgery \<3mths
* current significant acute injury affecting other lower extremity joints, or other relevant neurological or musculoskeletal pathology.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Lincoln

OTHER

Sponsor Role collaborator

United Lincolnshire Hospitals NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Prof David Mullineaux, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Lincoln

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

United Lincolnshire Hospitals NHS Trust

Lincoln, Lincolnshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

120614Mullineaux

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ACL Versus ALL + ACL Study
NCT03740022 COMPLETED NA